Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor women with polycystic ovary syndrome, weight that won't shift despite real effort is one of the most demoralising parts of the condition. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition — which PCOS can qualify as, subject to clinical assessment. Clinical trials in the SURMOUNT programme showed average body-weight reductions of around 20–21% over 72 weeks at the highest dose, though these trials were not PCOS-specific and individual results vary considerably. These are prescription-only medicines; a prescriber reviews your full medical picture before any treatment starts, and suitability for Mounjaro with PCOS is a clinical decision, not an automatic one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've probably been told to lose weight. You may have tried, more than once, with results that didn't reflect the effort you put in. That experience is real and well-documented: insulin resistance, which sits at the centre of PCOS for many women, disrupts how the body processes energy and stores fat. It also makes appetite regulation harder. So the frustration you might be feeling as you search this page makes complete sense.
Mounjaro works at a physiological level that's directly relevant here. By activating both GIP and GLP-1 receptors, it reduces appetite, slows how quickly food leaves the stomach, and improves the way the body handles blood sugar. None of those effects are PCOS-specific, but all of them address mechanisms that PCOS tends to work against. For a full picture of how the medicine functions, our Mounjaro overview covers the mechanism in detail.
What's less certain is how much of the weight-loss effect in clinical trials translates specifically to women with PCOS. The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled adults with obesity but not specifically women with PCOS; participants with type 2 diabetes were excluded. That means the headline figures (around 20–21% average weight loss at the maximum dose over 72 weeks) come from a broad population. Results in PCOS will vary, and a prescriber is the right person to set realistic expectations for your situation.
Some changes reported by women with PCOS on GLP-1 and dual-agonist therapies go beyond the number on the scales. Reductions in fasting insulin and improvements in menstrual regularity have been noted in smaller studies and case series, though these are not consistent findings and the evidence base specific to tirzepatide and PCOS is still developing. The NHS tirzepatide page gives a clear patient-level summary of what the medicine is licensed for and its known effects.
The general before-and-after arc for weight loss on Mounjaro tends to follow a recognisable pattern: a slower first month as the body adjusts to the starting dose, more noticeable changes from around weeks eight to twelve as the dose increases, and a different kind of plateau later as appetite regulation stabilises. If you want to see how those changes look in practice for real people, browsing those accounts alongside the early-weeks detail can help set realistic expectations. For an honest account of what the early weeks look like, results in the first week and what one month typically brings are worth reading before starting.
Contraception deserves a specific mention here. Women taking oral contraceptives should add a non-oral method for the first four weeks of Mounjaro and for four weeks after each dose increase, because absorption of the pill can be reduced. This is not optional advice. The NHS England guidance on weight-management injections sets this out plainly. If you are trying to conceive, Mounjaro is not appropriate; speak to your GP or specialist about timing before making any changes.
A PCOS diagnosis alone does not guarantee a prescription. The licensed criteria for Mounjaro require a BMI of 30 or above, or 27 or above alongside a weight-related health condition, PCOS can meet that second threshold, but the prescriber must also assess your full health picture: other conditions, current medications, contraindications, and your goals. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The decision is clinical, made by a real person, not a tick-box system.
At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it's submitted. There's no algorithm making suitability calls. How quickly results emerge and what the dose titration schedule looks like are questions the prescriber covers at review, not something to piece together from forums. If you'd like to understand the team behind those reviews, our clinical team page explains who's involved.
For anyone weighing up the private route, the cost context for Mounjaro in the UK and the broader treatment options available are worth looking at before you decide. When you're ready, checking your eligibility takes a few minutes and costs nothing.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.